New insulin system tested in hotel study – no severe events reported
NCT ID NCT06428591
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This small study tested a new insulin delivery system called Tandem Freedom in 10 adults with type 1 diabetes. Participants first used their usual system at home for a week, then switched to Tandem Freedom in a supervised hotel setting. The main goals were to check for severe low blood sugar or diabetic ketoacidosis events. The study was completed and focused on safety and glucose control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 1 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Otago
Christchurch, 8140, New Zealand
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a stress hormone be behind the hidden danger of low blood sugar?
- Can a peptide tame type 1 diabetes?
- Can a tiny implant track glucose, ketones, and lactate in diabetes?
- Wearable sensor could unmask hidden blood sugar chaos in stomach paralysis
- A smarter insulin that aims for the liver could curb dangerous nighttime dips
- Smart insulin pump may boost brain and body health in older adults with diabetes